YARDLEY, PA — Optinose (NASDAQ:OPTN) has appointed Terry Kohler as its new Chief Financial Officer, a strategic addition to the company’s executive team aimed at driving financial leadership and growth. Kohler comes to Optinose with over two decades of finance expertise, most recently serving as CFO at Verrica Pharmaceuticals. There, he played a crucial role in commercial preparations for a dermatology product launch and led pipeline investments.
Ramy Mahmoud, MD, MPH, CEO of Optinose, expressed enthusiasm about Kohler’s appointment, stating, “We are pleased to add Terry to our leadership team to help guide the company into the future. His experience in leading financial strategy for commercial stage branded pharmaceutical products will be extremely helpful as we work to maximize the value of our company and of XHANCE as a treatment for patients with chronic rhinosinusitis.”
Before his role at Verrica, Kohler held key positions at Endo International PLC, including Vice President of Corporate Development. He also has a background in investment banking and completed the MBA Leadership Development program at Johnson & Johnson. Kohler holds a B.A. in International Business and Management from Dickinson College and an MBA in Finance & Entrepreneurship from the University of North Carolina, and he is a Certified Management Accountant.
On joining Optinose, Kohler shared, “I am pleased to join the highly focused Optinose team at an early stage in the transition of XHANCE from a narrow niche indication towards a new indication with significant future potential. Given the large chronic sinusitis market, multiple potential growth opportunities for the brand, and range of future strategic paths available, it is an exciting time to be joining the Company.”
As part of his appointment, Kohler was granted a non-qualified stock option and restricted stock units as an inducement to join Optinose. These grants are structured to vest over four years, contingent on his continued service, aligning his interests with the long-term success of the company.
Kohler’s appointment is poised to strengthen Optinose’s financial strategies as it navigates new growth opportunities and enhances its market position in treating chronic sinusitis.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.